Bank of New York Mellon Corp Reduces Position in Illumina, Inc. $ILMN

Bank of New York Mellon Corp decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 7.6% during the 1st quarter, HoldingsChannel reports. The fund owned 1,500,016 shares of the life sciences company’s stock after selling 123,419 shares during the quarter. Bank of New York Mellon Corp’s holdings in Illumina were worth $184,892,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Elyxium Wealth LLC acquired a new stake in Illumina during the 4th quarter valued at approximately $25,000. Board of the Pension Protection Fund purchased a new stake in Illumina during the 4th quarter worth approximately $26,000. Creative Capital Management Investments LLC raised its position in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina in the 4th quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in shares of Illumina during the 4th quarter valued at approximately $26,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Piper Sandler raised their price target on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. Citigroup increased their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Barclays boosted their target price on shares of Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a research report on Wednesday, June 24th. Nine research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $156.88.

Insider Buying and Selling

In other news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,003,769 shares of company stock worth $155,710,908. Company insiders own 2.90% of the company’s stock.

Illumina Stock Performance

ILMN stock opened at $186.65 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The firm has a market cap of $28.24 billion, a P/E ratio of 33.94, a P/E/G ratio of 3.49 and a beta of 1.47. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $196.66. The stock’s 50 day simple moving average is $166.44 and its 200 day simple moving average is $143.34.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 5.22 EPS for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.